Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Target Price at $32.17

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given a consensus rating of “Moderate Buy” by the eight brokerages that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $32.1667.

A number of research firms have recently weighed in on CPRX. Oppenheimer cut Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Zacks Research raised Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Finally, Citigroup cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $35.00 to $31.50 in a report on Friday, May 8th.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in Catalyst Pharmaceuticals by 16.2% during the first quarter. Janus Henderson Group PLC now owns 1,998,875 shares of the biopharmaceutical company’s stock worth $49,520,000 after purchasing an additional 279,108 shares in the last quarter. Amundi raised its holdings in Catalyst Pharmaceuticals by 68.4% during the first quarter. Amundi now owns 31,463 shares of the biopharmaceutical company’s stock worth $779,000 after purchasing an additional 12,778 shares in the last quarter. California State Teachers Retirement System raised its holdings in Catalyst Pharmaceuticals by 27.9% during the first quarter. California State Teachers Retirement System now owns 140,716 shares of the biopharmaceutical company’s stock worth $3,484,000 after purchasing an additional 30,717 shares in the last quarter. Empowered Funds LLC raised its holdings in Catalyst Pharmaceuticals by 6.8% during the first quarter. Empowered Funds LLC now owns 102,096 shares of the biopharmaceutical company’s stock worth $2,528,000 after purchasing an additional 6,539 shares in the last quarter. Finally, Quantinno Capital Management LP raised its holdings in Catalyst Pharmaceuticals by 180.2% during the first quarter. Quantinno Capital Management LP now owns 33,885 shares of the biopharmaceutical company’s stock worth $839,000 after purchasing an additional 21,794 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 0.2%

CPRX opened at $31.23 on Friday. The business’s 50 day moving average is $26.28 and its 200-day moving average is $24.42. The stock has a market cap of $3.82 billion, a PE ratio of 17.95, a price-to-earnings-growth ratio of 0.91 and a beta of 0.72. Catalyst Pharmaceuticals has a twelve month low of $19.05 and a twelve month high of $32.56.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).